Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Genz-644470 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo matched to Genz-644470 tablet orally three times a day (TID) with meals for 3 weeks. |
| Genz-644470 2.4 Grams Per Day (g/day) | EXPERIMENTAL | Genz-644470 2.4 g/day tablets dosed orally TID with meals for 3 weeks. |
| Genz-644470 4.8 g/day | EXPERIMENTAL | Genz-644470 4.8 g/day tablets dosed orally TID with meals for 3 weeks. |
| Genz-644470 7.2 g/day | EXPERIMENTAL | Genz-644470 7.2 g/day tablets dosed orally TID with meals for 3 weeks. |
| Sevelamer Carbonate 2.4 g/day | ACTIVE_COMPARATOR | Sevelamer Carbonate 2.4 g/day tablets dosed orally TID with meals for 3 weeks. |
| Sevelamer Carbonate 4.8 g/day | ACTIVE_COMPARATOR | Sevelamer Carbonate 4.8 g/day tablets dosed orally TID with meals for 3 weeks. |
| Sevelamer Carbonate 7.2 g/day | ACTIVE_COMPARATOR | Sevelamer Carbonate 7.2 g/day tablets dosed orally TID with meals for 3 weeks. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | - |
| Genz-644470 | DRUG | - |
| Sevelamer carbonate | DRUG | - |
Inclusion Criteria: * Serum phosphate level greater than (\>) 5.5 milligram per deciliter (mg/dL) (1.78 millimole per liter \[mmol/L\]) after discontinuation of current phosphate binder therapy * Men or women 18 years or older Exclusion Criteria: * Have active dysphagia or swallowing disorder or ...
Genz-644470 is an investigational small molecule being studied for the treatment of chronic kidney failure. It was evaluated in a Phase 2 clinical trial in patients with chronic kidney disease on hemodialysis. The drug is not approved and remains in clinical development.
Genz-644470 is being developed by Sanofi, a multinational pharmaceutical company traded on the stock exchange under the ticker symbol SNY. The drug is an investigational small molecule in Phase 2 clinical development for chronic kidney failure.
Genz-644470 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study. The drug is investigational and has not been approved by regulatory authorities.
Genz-644470 has one completed clinical trial, identified as NCT00853242. This Phase 2 study compared Genz-644470, placebo, and sevelamer carbonate in chronic kidney disease patients on hemodialysis. The trial enrolled 349 participants in the United States and Puerto Rico.
Genz-644470 is a small molecule, but its specific molecular target has not been disclosed. In a Phase 2 trial, it was compared against sevelamer carbonate, a phosphate binder, in chronic kidney disease patients on hemodialysis, suggesting it may affect phosphate metabolism, though this is not confirmed.